Clinical trial
To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active…
NCT00050648 · Rockefeller University, Other · Completed
Key facts
| NCT number | NCT00050648 |
|---|---|
| Title | To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris |
| Official title | Use of Humanized CD25 (Anti-TAC) Monoclonal Antibody and Cyclosporine for the Treatment of Active Psoriasis. |
| Lead sponsor | Rockefeller University, Other |
| Collaborators | Facet Biotech Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Daclizumab, Cyclosporine, cyclosporine and Daclizumab |
| Enrollment | 20 |
| Start date | Oct 1, 1997 |
| Primary completion | Sep 1, 2004 |
| Completion | Apr 1, 2008 |
| First posted | Dec 18, 2002 |
| Last update posted | Mar 13, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: